Advertisement

Malignant Fibrous, Fibrohistiocytic, and Myofibroblastic Tumors

  • Aaron M. Udager
  • Reena Singh
  • Steven D. Billings
  • Rajiv M. Patel
Chapter

Abstract

This chapter covers fibrous, fibrohistiocytic, and myofibroblastic tumors that have metastatic potential. Congenital/infantile fibrosarcoma is the exception to that rule, as it behaves less aggressively than its adult counterpart. Adult-type fibrosarcoma is a diagnosis in decline due to the recognition of distinct variants: low-grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma, myxofibrosarcoma, low-grade myofibroblastic sarcoma (myofibrosarcoma), and myxoinflammatory fibroblastic sarcoma. Undifferentiated pleomorphic sarcoma may also present as a superficial tumor and will be briefly discussed. The chapter closes with a discussion of undifferentiated pleomorphic sarcomas of the skin, specifically atypical fibroxanthoma and pleomorphic dermal sarcoma.

Keywords

Congenital/infantile fibrosarcoma Adult-type fibrosarcoma Low-grade fibromyxoid sarcoma Sclerosing epithelioid fibrosarcoma Myxofibrosarcoma Low-grade myofibroblastic sarcoma (myofibrosarcoma) Myxoinflammatory fibroblastic sarcoma Undifferentiated pleomorphic sarcoma Atypical fibroxanthoma Pleomorphic dermal sarcoma 

Selected References

  1. 1.
    Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM. Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol. 2001;25(6):699–709.PubMedCrossRefGoogle Scholar
  2. 2.
    Arbajian E, Puls F, Magnusson L, Thway K, Fisher C, Sumathi VP, Tayebwa J, Nord KH, Kindblom LG, Mertens F. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2014;38(6):801–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Argani P, Fritsch M, Kadkol SS, Schuster A, Beckwith JB, Perlman EJ. Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors. Mod Pathol. 2000;13(1):29–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Bahrami A, Folpe AL. Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol. 2010;34(10):1504–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Billings SD, Giblen G, Fanburg-Smith JC. Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population. Am J Surg Pathol. 2005;29(2):204–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Brenn T. Pleomorphic dermal neoplasms: a review. Adv Anat Pathol. 2014;21(2):108–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Carter JM, Sukov WR, Montgomery E, Goldblum JR, Billings SD, Fritchie KJ, Folpe AL. TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms. Am J Surg Pathol. 2014;38(9):1182–992.PubMedCrossRefGoogle Scholar
  8. 8.
    Choy B, Hyjek E, Montag AG, Pytel P, Haydon R, Luu HH, Zhen CJ, Long BC, Kadri S, Segal JP, Furtado LV, Cipriani NA. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma. Histopathology. 2017;70(5):734–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer. 1976;38(2):729–39.PubMedCrossRefGoogle Scholar
  10. 10.
    Clarke LE, Zhang PJ, Crawford GH, Elenitsas R. Myxofibrosarcoma in the skin. J Cutan Pathol. 2008;35(10):935–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Coffin CM, Dehner LP. Fibroblastic-myofibroblastic tumors in children and adolescents: a clinicopathologic study of 108 examples in 103 patients. Pediatr Pathol. 1991;11(4):569–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Davis JL, Lockwood CM, Albert CM, Tsuchiya K, Hawkins DS, Rudzinski ER. Infantile NTRK-associated mesenchymal tumors. Pediatr Dev Pathol. 2018;21(1):68–78.PubMedCrossRefGoogle Scholar
  13. 13.
    de Feraudy S, Mar N, McCalmont TH. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol. 2008;32(8):1111–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, Sannaa GA, Ingram D, Wang WL, Ravi V, Guadagnolo A, Lev D, Pollock RE, Hunt K, Cormier J, Lazar A, Feig B, Torres KE. Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions. Ann Surg Oncol. 2015;22(12):3913–20.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Evans HL. Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol. 1987;88(5):615–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Evans HL. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up. Am J Surg Pathol. 2011;35(10):1450–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Fisher C. Myofibrosarcoma. Virchows Arch. 2004;445(3):215–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Folpe AL, Lane KL, Paull G, Weiss SW. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol. 2000;24(10):1353–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, Schadendorf D, Mentzel T. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol. 2014;27(4):502–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Guillou L, Benhattar J, Gengler C, Gallagher G, Ranchère-Vince D, Collin F, Terrier P, Terrier-Lacombe MJ, Leroux A, Marquès B, Aubain Somerhausen Nde S, Keslair F, Pedeutour F, Coindre JM. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French sarcoma group. Am J Surg Pathol. 2007;31(9):1387–402.PubMedCrossRefGoogle Scholar
  21. 21.
    Kao YC, Fletcher CDM, Alaggio R, Wexler L, Zhang L, Sung YS, Orhan D, Chang WC, Swanson D, Dickson BC, Antonescu CR. Recurrent BRAF gene fusions in a subset of pediatric spindle cell sarcomas: expanding the genetic Spectrum of tumors with overlapping features with infantile Fibrosarcoma. Am J Surg Pathol. 2018;42(1):28–38.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Laskin WB, Fetsch JF, Miettinen M. Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome. Am J Surg Pathol. 2014;38(1):1–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Lucas DR. Myxoinflammatory fibroblastic sarcoma: review and update. Arch Pathol Lab Med. 2017;141(11):1503–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Luzar B, Calonje E. Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J Cutan Pathol. 2010;37(3):301–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Magro G, Salvatorelli L, Vecchio GM, Musumeci G, Rita A, Parenti R. Cytoplasmic expression of Wilms tumor transcription factor-1 (WT1): a useful immunomarker for young-type fibromatoses and infantile fibrosarcoma. Acta Histochem. 2014;116(7):1134–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther. 2009;9(8):1135–44.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Meis-Kindblom JM, Kindblom LG. Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol. 1998;22(8):911–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol. 1995;19(9):979–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20(4):391–405.PubMedCrossRefGoogle Scholar
  30. 30.
    Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Investig. 2005;85(3):408–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Michal M, Kazakov DV, Hadravský L, Kinkor Z, Kuroda N, Michal M. High-grade myxoinflammatory fibroblastic sarcoma: a report of 23 cases. Ann Diagn Pathol. 2015;19(3):157–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Mihic-Probst D, Zhao J, Saremaslani P, Baer A, Oehlschlegel C, Paredes B, Komminoth P, Heitz PU. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res. 2004;24(1):19–26.PubMedGoogle Scholar
  33. 33.
    Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012;36(9):1317–26.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol. 2005;46(4):235–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Montgomery E, Goldblum JR, Fisher C. Myofibrosarcoma: a clinicopathologic study. Am J Surg Pathol. 2001;25(2):219–28.PubMedCrossRefGoogle Scholar
  36. 36.
    Nascimento AF, Bertoni F, Fletcher CD. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol. 2007;31(1):99–105.PubMedCrossRefGoogle Scholar
  37. 37.
    Patel RM, Downs-Kelly E, Dandekar MN, Fanburg-Smith JC, Billings SD, Tubbs RR, Goldblum JR. FUS (16p11) gene rearrangement as detected by fluorescence in-situ hybridization in cutaneous low-grade fibromyxoid sarcoma: a potential diagnostic tool. Am J Dermatopathol. 2011;33(2):140–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Pritchard DJ, Soule EH, Taylor WF, Ivins JC. Fibrosarcoma--a clinicopathologic and statistical study of 199 tumors of the soft tissues of the extremities and trunk. Cancer. 1974;33(3):888–97.PubMedCrossRefGoogle Scholar
  39. 39.
    Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016;25(4):775–88.PubMedCrossRefGoogle Scholar
  40. 40.
    Sakamoto A, Oda Y, Itakura E, Oshiro Y, Nikaido O, Iwamoto Y, Tsuneyoshi M. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol. 2001a;14(6):581–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Sakamoto A, Oda Y, Itakura E, Oshiro Y, Tamiya S, Honda Y, Ishihara A, Iwamoto Y, Tsuneyoshi M. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum Pathol. 2001b;32(11):1225–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Scoccianti G, Ranucci V, Frenos F, Greto D, Beltrami G, Capanna R, Franchi A. Soft tissue myxofibrosarcoma: A clinicopathological analysis of a series of 75 patients with emphasis on the epithelioid variant. J Surg Oncol. 2016;114(1):50–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Sheng WQ, Hisaoka M, Okamoto S, Tanaka A, Meis-Kindblom JM, Kindblom LG, Ishida T, Nojima T, Hashimoto H. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol. 2001;115(3):348–55.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith SC, Poznanski AA, Fullen DR, Ma L, McHugh JB, Lucas DR, Patel RM. CD34-positive superficial myxofibrosarcoma: a potential diagnostic pitfall. J Cutan Pathol. 2013;40(7):639–45.PubMedCrossRefGoogle Scholar
  45. 45.
    Tardío JC, Pinedo F, Aramburu JA, Suárez-Massa D, Pampín A, Requena L, Santonja C. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol. 2016;43(2):101–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Tjarks BJ, Ko JS, Billings SD. Myxofibrosarcoma of unusual sites. J Cutan Pathol. 2018;45(2):104–10.PubMedCrossRefGoogle Scholar
  47. 47.
    Variend S, Bax NM, van Gorp J. Are infantile myofibromatosis, congenital fibrosarcoma and congenital haemangiopericytoma histogenetically related? Histopathology. 1995;26(1):57–62.PubMedCrossRefGoogle Scholar
  48. 48.
    Vernon SE, Bejarano PA. Low-grade fibromyxoid sarcoma: a brief review. Arch Pathol Lab Med. 2006;130(9):1358–60.PubMedGoogle Scholar
  49. 49.
    Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41(6):2250–66.PubMedCrossRefGoogle Scholar
  50. 50.
    Willems SM, Mohseny AB, Balog C, Sewrajsing R, Briaire-de Bruijn IH, Knijnenburg J, Cleton-Jansen AM, Sciot R, Fletcher CD, Deelder AM, Szuhai K, Hensbergen PJ, Hogendoorn PC. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 2009;13(7):1291–1301. doi:  https://doi.org/10.1111/j.1582-4934.2009.00747.x. Epub 2009 Mar 13.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Aaron M. Udager
    • 1
  • Reena Singh
    • 2
  • Steven D. Billings
    • 3
  • Rajiv M. Patel
    • 1
  1. 1.Department of PathologyUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Department of PathologyOregon Health and Science University School of MedicinePortlandUSA
  3. 3.Department of PathologyCleveland ClinicClevelandUSA

Personalised recommendations